Oprah Winfrey GLP-1: Comparison to Similar Public Figures

What GLP-1 Medication Did Oprah Winfrey Confirm Using?

Oprah Winfrey confirmed in a December 2023 interview with People magazine that she had begun using a GLP-1 receptor agonist as one component of a broader weight-management program that also included diet changes and walking. She did not name the specific drug. The GLP-1 class includes FDA-approved agents semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), as well as liraglutide (Saxenda) [1].

Why She Did Not Name the Drug

Oprah's decision to disclose the class but not the molecule is consistent with how several public figures have handled these statements. Naming the brand creates direct endorsement implications. Her legal and communications teams almost certainly shaped that framing. Clinically, the distinction matters because semaglutide 2.4 mg (Wegovy) and tirzepatide 15 mg (Zepbound) produce meaningfully different weight-loss outcomes in trial data [2, 3].

The WeightWatchers Connection

Oprah joined the WeightWatchers board in 2015 and held approximately 10% equity in the company. Her January 2024 board resignation, announced shortly after her GLP-1 disclosure, removed a perceived conflict of interest. WeightWatchers has since rebranded its clinical arm to include GLP-1 prescribing services, acknowledging that medication and behavioral programs are not mutually exclusive [4].

The company's own pivot mirrors what the American Gastroenterological Association stated in its 2022 clinical practice guideline: "Pharmacotherapy should be offered as an adjunct to intensive lifestyle intervention for adults with obesity." Oprah's public arc, from behavioral program advocate to medication user, reflects that same clinical repositioning happening across the field.

How GLP-1 Drugs Actually Work

GLP-1 receptor agonists bind to receptors in the hypothalamus, brainstem, and gut. The binding suppresses glucagon secretion, stimulates insulin release in a glucose-dependent manner, and slows gastric emptying, all of which reduce caloric intake and improve postprandial glucose control [5].

Semaglutide's Clinical Evidence Base

The STEP-1 trial (N=1,961) tested semaglutide 2.4 mg subcutaneous once weekly versus placebo over 68 weeks in adults with BMI <30 kg/m2 who also had at least one weight-related comorbidity or BMI >30 kg/m2. Mean weight loss was 14.9% in the semaglutide group versus 2.4% in the placebo group (P<0.001) [2]. Those results published in the New England Journal of Medicine in 2021 were the basis for the FDA's June 2021 approval of Wegovy.

Tirzepatide's Dual-Agonist Advantage

Tirzepatide activates both GIP and GLP-1 receptors. In SURMOUNT-1 (N=2,539), the 15 mg dose produced mean weight loss of 20.9% at 72 weeks versus 3.1% with placebo [3]. The FDA approved tirzepatide (Zepbound) for chronic weight management in November 2023, the same month Oprah's interview circulated.

Comparison to Other Public Figures Who Disclosed GLP-1 Use

Several celebrities and business figures disclosed GLP-1 or related weight-loss drug use between 2022 and 2024. The disclosures varied widely in specificity and clinical framing.

Elon Musk

Musk posted on X in October 2022 that he was using Wegovy (semaglutide 2.4 mg) combined with intermittent fasting. His posts named the drug explicitly. He reported losing roughly 30 lb but did not disclose his starting weight, BMI, or any physician oversight. His comments drew attention partly because Wegovy was still in limited supply at that time following manufacturing shortages that the FDA documented in 2022 [6].

Musk's framing positioned the drug as a personal optimization tool rather than a treatment for obesity as a disease. That framing diverges from how the FDA labels semaglutide 2.4 mg, which specifies use "as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m2 or greater, or 27 kg/m2 or greater in the presence of at least one weight-related comorbidity" [1].

Sharon Osbourne

Sharon Osbourne disclosed in a 2023 interview that she had used Ozempic (semaglutide 1 mg, the diabetes-labeled formulation) and lost approximately 42 lb. She later stated she had become "too thin" and had stopped the medication. Her comments drew clinical commentary because Ozempic is FDA-approved for type 2 diabetes management, not obesity, though off-label prescribing for weight management is legal and common [1].

Her experience illustrates a real clinical concern. GLP-1-mediated weight loss can overshoot the intended target when patients do not have structured dietary guidance. Muscle mass loss is a documented side effect; one 2022 study in Obesity found that roughly 39% of weight lost with semaglutide consisted of lean mass rather than fat in some trial subgroups [7].

Kelly Clarkson

Kelly Clarkson confirmed in a January 2024 interview that she was using a weight-loss medication she described as "not Ozempic" and clarified it was a different drug. She did not specify tirzepatide or liraglutide by name. Clarkson also disclosed a thyroid condition, which is clinically relevant because GLP-1 receptor agonists carry an FDA-boxed warning for thyroid C-cell tumors observed in rodent studies; the label states the drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [1]. Clarkson's physician team would presumably have screened for that history.

Comparing the Four Disclosures

The table below summarizes how Oprah's disclosure compares to three other high-profile cases across six clinical and communications variables. This framework was developed by the HealthRX medical team to give readers a structured way to evaluate celebrity medication disclosures.

| Variable | Oprah Winfrey | Elon Musk | Sharon Osbourne | Kelly Clarkson | |---|---|---|---|---| | Drug named? | No (class only) | Yes (Wegovy) | Yes (Ozempic) | No ("not Ozempic") | | Physician oversight mentioned? | Yes | No | Not confirmed | Yes | | Diet/lifestyle adjunct mentioned? | Yes | Yes (IF) | No | Yes | | Outcome quantified? | No | ~30 lb | ~42 lb | No | | Stopped medication? | Not disclosed | Not confirmed | Yes | Not disclosed | | FDA-approved indication met? | Likely (BMI criteria) | Unknown | Off-label use | Unknown |

The most clinically complete disclosure in this group is Musk's, paradoxically, because he named the exact drug and dose tier, enabling any treating physician reviewing the statement to cross-reference prescribing information. Osbourne's disclosure is the most clinically concerning because of the apparent absence of structured monitoring and the overshoot outcome she described.

What Oprah's Disclosure Means for Patients Considering GLP-1 Therapy

Oprah's public acknowledgment of GLP-1 use carried weight beyond celebrity news. She had been one of the most visible spokespeople for behavioral weight-loss programs for nearly a decade. Her pivot signaled, for millions of viewers, that medication assistance is not a personal failure.

The Stigma Signal

A 2021 survey published in Obesity Science and Practice found that 65% of adults with obesity reported feeling stigmatized when discussing weight management medications with their primary care providers [8]. High-profile disclosures like Oprah's may reduce that barrier. The Obesity Society's 2023 clinical practice guidelines note that obesity is a "chronic, relapsing, multifactorial disease" and recommend against framing pharmacotherapy as a last resort [9].

The Supply and Access Problem

Semaglutide (Wegovy) remained on the FDA drug shortage list from mid-2022 through much of 2023 [6]. Increased demand following celebrity disclosures likely extended that shortage. A June 2023 analysis in JAMA found that GLP-1 prescriptions for weight management increased 300% between 2020 and 2023, with the steepest increase occurring in late 2022 and early 2023, corresponding with high-profile public mentions [10].

Patients who cannot access branded semaglutide or tirzepatide sometimes turn to compounded versions from 503B outsourcing facilities. The FDA has issued guidance stating that compounded semaglutide is not FDA-approved and may not meet the same safety and efficacy standards as the branded product [6]. That distinction is absent from nearly all celebrity-level discussion of these drugs.

Insurance Coverage Reality

Medicare began covering Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease following the SELECT trial results in March 2024, which showed a 20% reduction in major adverse cardiovascular events (MACE) in adults with obesity and pre-existing cardiovascular disease (N=17,604, 33 months median follow-up) [11]. Private insurance coverage for weight management indications remains inconsistent. Most patients paying out of pocket for Wegovy face list prices exceeding $1,300 per month, a barrier not present for the public figures discussed in this article.

Clinical Criteria for GLP-1 Therapy

The FDA label for Wegovy specifies the following criteria [1]:

• BMI >30 kg/m2, OR
• BMI >27 kg/m2 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

Absolute contraindications include personal or family history of MTC, MEN2, and known hypersensitivity to semaglutide or any excipient. Common side effects include nausea (44% of patients in STEP-1), vomiting (24%), diarrhea (30%), and constipation (24%) [2].

The standard titration for semaglutide 2.4 mg starts at 0.25 mg subcutaneous weekly for 4 weeks, increasing by 0.25 mg every 4 weeks to reach the maintenance dose of 2.4 mg at week 16 or 17 [1]. Tirzepatide (Zepbound) starts at 2.5 mg weekly and titrates by 2.5 mg every 4 weeks to a maximum of 15 mg [3].

What Stopping GLP-1 Therapy Looks Like

Sharon Osbourne's reported outcome after stopping raises a clinical issue that deserves direct attention. A 2022 study in Diabetes, Obesity and Metabolism (N=327) found that participants regained two-thirds of weight lost during a 68-week semaglutide course within one year of stopping the drug [12]. The authors concluded that continued treatment is required to maintain weight-loss benefits.

This is not unique to GLP-1 agents. Weight regain after stopping any anti-obesity pharmacotherapy follows a similar trajectory and reflects the chronic, neurobiological nature of obesity rather than patient non-adherence. Clinicians at the American Association of Clinical Endocrinology (AACE) have described obesity management as "requiring the same long-term, ongoing approach as other chronic conditions such as hypertension or diabetes" in their 2023 guidelines [13].

Patients considering stopping GLP-1 therapy should do so with a structured tapering plan and active transition to a maintenance-focused dietary and physical activity program.